CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2004-10-06): Roche hepatitis C drugs win fast review for use in HIV patients

Regulatory

Roche hepatitis C drugs win fast review for use in HIV patients

Last Updated: 2004-10-06 15:57:19 -0400 (Reuters Health)

NEW YORK (Reuters) - Roche Holding SA on Wednesday said U.S. regulators would give priority review to whether the company's combination treatment for hepatitis C should be used by patients also infected with HIV.

Roche's injectable interferon Pegasys and oral ribavirin are already approved for the treatment of hepatitis C virus infection. Since a significant percentage of people infected with HIV are also infected with the hepatitis C virus, Roche has asked for permission to market the dual therapy for this population.

Drugs given priority review status are reviewed by the U.S. Food and Drug Administration within six months, rather than the typical review time of up to one year.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.